Like many aspects of life sciences today, speaker programs are being cut due to budgetary constraints and the tightening regulatory landscape. I read a recent article by Bill Cooney in PharmaExec that highlighted this trend, reporting that speaker program activity is down 30 percent or more at most pharmaceutical companies.Read More →